Back to results
US 11,633,450 B2Granted
Treatment of HMGB1-mediated inflammation
AssigneeThe Feinstein Institute for Medical Research
InventorsKevin J. Tracey, Huan Yang, Yousef Al-Abed
Life of this patent
Estimating the term…
Abstract
Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.
Claims2
A composition comprising a peptide consisting of the amino acid sequence FSSE (SEQ ID NO:
- 1) and a pharmaceutically acceptable carrier wherein the pharmaceutically acceptable carrier is selected from the group consisting of isotonic saline, alcohol, phosphate buffered saline, balanced salt solution, and dimethylsulfoxide (DMSO).
Dependencies are inferred from the claim text.